| Literature DB >> 31273587 |
Helen C O'Neill1, Maya Nikoloska2,3, HiuTung Ho2,4, Alpesh Doshi5, Walid Maalouf6.
Abstract
STUDY QUESTION: Does cryoprotection of spermatozoa using a vitrification protocol with improved cryoprotective agents and a novel device for large storage lead to better outcomes than conventional slow freezing? Vitrification of human sperm using sucrose and dextran-based cryoprotectant (CPA4) with a new vitrification device resulted in significantly better sperm motility and progressive motility and improved DNA integrity with lower DNA fragmentation compared with conventional slow freezing. WHAT IS KNOWN ALREADY: A major limitation to clinical implementation of vitrification is the right balance between the volume of spermatozoa suspension cryopreserved and a standardised use of CPAs for survival of spermatozoa. STUDY DESIGN, SIZE, DURATION: This was a control versus current clinical practice study using 30 fresh human semen samples to carry out the different cryoprotectant analyses followed by a further 23 semen samples to test the novel vitrification protocol. PARTICIPANTS/MATERIALS, SETTING,Entities:
Keywords: Cryoprotectants; Slow-freezing; Sperm; Vitrification
Mesh:
Substances:
Year: 2019 PMID: 31273587 PMCID: PMC6707954 DOI: 10.1007/s10815-019-01505-x
Source DB: PubMed Journal: J Assist Reprod Genet ISSN: 1058-0468 Impact factor: 3.412
Fig. 1Diagram and photo of the vitrification device and the vitrification process. Twenty microlitres of post-preparation sperm suspension are loaded just above the vitrification device that pre-immersed in liquid nitrogen
Comparison of spermatozoa survival rates using 5 different cryoprotectants (CPA1-CPA5) to the post-density gradient control. Numbers given are mean ± SD, *p < 0.05, +/−p < 0.05 (CPA1 to CPA5 comparison excluding control)
| Control | CPA1 | CPA2 | CPA3 | CPA4 | CPA5 | |
|---|---|---|---|---|---|---|
| Concentration (M/mL) | 46.8* (± 61.1) | 23 (± 15.9) | 15.7 (± 18.0) | 17 (± 20.2) | 14.2 (± 15.5) | 14.4 (± 15.6) |
| Total motility (PM + NP, %) | 82.2* (± 13.8) | 17.7 (± 9.4) | 18.6 (± 9.2) | 21.9 (± 8.9) | 31.2+ (± 11.4) | 2.4− (± 2.1) |
| Progressive motility (%) | 53.2* (± 25.8) | 5.6 (± 4.3) | 5.2 (± 4.9) | 9.8 (± 6.4) | 15.5+ (± 8.6) | 0.8− (± 1.0) |
| DAP (μm) | 15.5* (± 6.7) | 11.4 (± 6.0) | 10.5 (± 6.2) | 14.3* (± 7.9) | 14.0* (± 7.7) | 10.0 (± 6.4) |
| DCL (μm) | 26.9* (± 12.4) | 23.8 (± 11.8) | 22.4 (± 12.5) | 27.5* (± 13.9) | 26.8* (± 13.8) | 21.0 (± 13.6) |
| DSL (μm) | 9.7* (± 5.0) | 7.9* (± 5.4) | 7.1 (± 5.5) | 10.7*+ (± 7.3) | 10.4*+ (± 7.1 | 6.4 (± 4.9) |
| LIN (VSL/VCL, %) | 37.8* (± 16.5) | 33.7* (± 16.0) | 31.2 (± 16.5) | 38.3* (± 16.2) | 38.0* (± 16.0) | 35.0* (± 19.7) |
| STR (VSL/VAP, %) | 64.9 (± 20.8) | 66.4 (± 20.1) | 64.6 (± 20.9) | 71.8 (± 16.2) | 70.3 (± 19.5) | 65.1 (± 24.4) |
Fig. 2Mean (%) ± SD of PM (progressive motile), NP (non-progressive motile), and IM (immotile) of post-prep test wash samples prior to freezing and post-thawed samples cryopreserved by the 6 different protocols; different letters between groups indicate statistically significant differences at p < 0.05
Comparison of semen parameters between control and frozen/thawed or vitrified/warmed samples. Values are expressed as mean ± SD, *+−p < 0.05
| Sperm concentration | Motility (PM + NP) | Progressive motility (PM) | DNA fragmentation | |
|---|---|---|---|---|
| Control | 30.1 ± 28.2* | 77.8 ± 18.2* | 49.5 ± 23.3* | 16.3 ± 12.9 |
| Slow freezing | 9.7 ± 11.2 | 21.2 ± 10.2− | 7.2 ± 6.2- | 25.5 ± 17.1* |
| Vitrification | 10.0 ± 13.9 | 30.1 ± 10.9+ | 16.2 ± 7.4+ | 18.1 ± 12.8 |